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Human pancreatic cancer cell lines do not express receptors for
somatostatin
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Summary The in vivo administration of somatostatin (SS) or its analogues is capable of suppressing the
growth of pancreatic cancer in experimental animals. We examined the effects of SS-14 and its analogue
RC-160 on the in vitro growth of two human pancreatic cancer cell lines MiaPaCa-2 and Panc-1 stimulated
with epidermal growth factor (EGF) or insulin-like growth factor 1 (IGF-1). Neither SS-14 nor RC-160
inhibited the growth of either cell line. In contrast RC-160 did inhibit the EGF-stimulated growth of a rat
pancreatic cancer cell line AR42J. Binding studies with '251-Tyr" somatostatin revealed the presence of a single
class of high affinity binding sites with a Kd of 0.20 ± 0.05 nM and a B.,,, of 2.1 + 0.26 pmoles mg-' protein on
AR42J but no displaceable binding was observed on MiaPaCa-2 or Panc-1. We conclude that lack of receptors
accounts for the failure of SS-14 and RC-160 to influence the growth of human pancreatic cancer in vitro.
These results, taken together with other findings, lead us to question the therapeutic efficacy of somatostatin
and its analogues as mono-therapy in the treatment of human pancreatic cancer.
Somatostatin (SS) is a tetradecapeptide widely distributed
throughout the body, being found in high concentrations in
the brain, stomach, intestine and pancreas (Reichlin, 1983).
Somatostatin exerts inhibitory actions on the cellular func-
tions within a variety of tissues including secretion and
growth (Konturek et al., 1988; Meyers & Coy, 1980; Schally,
1988). Somatostatin inhibits the pancreatic exocrine secretion
of protein and bicarbonate (Boden et al., 1975) and the
endocrine secretion of cholecystokinin, gastrin and secretin
(Schally et al., 1978). These hormones have been shown to
have trophic effects on the growth of normal pancreas and
also on pancreatic tumours (Johnson, 1981; Schally et al.,
1986). It has therefore been proposed that somatostatin may
be capable of inhibiting pancreatic tumour growth indirectly
via the suppression of secretion of pancreatic trophic hor-
mones and/or by direct effects on the tumour itself (Schally
et al., 1988; Liebow et al., 1989). Redding et al. (1984)
described the inhibition ofboth rat and hamster experimental
pancreatic cancer growth by the administration of somato-
statin-14. Subsequently, Upp et al. (1988) reported that the
somatostatin analogue SMS 201-995 inhibited the growth of
two xenografted human pancreatic cancers in nude mice.
Singh and colleagues (1991) have since shown that one of
these xenografts expressed specific binding sites for somato-
statin. It has been claimed that in vitro, somatostatin-14, and
its analogue RC-160, reverse the growth-potentiating effects
of epidermial growth factor (EGF) on the human pancreatic
carcinoma cell line MiaPaCa-2 (Liebow et al., 1986) through
the promotion of tyrosine phosphatase activity (Liebow et
al., 1989). For somatostatin to impair directly the growth of
pancreatic cancer the cells should therefore express receptors
for the peptide. The aim of these study was to determine the
somatostatin receptor status of two human (MiaPaCa-2 &
Panc-1) and a rat (AR42J) pancreatic cancer cell lines. We
have also studied the effects of somatostatin-14 and RC-160
on the proliferation of these three cell lines.
Materials and methods
Cell growth
MiaPaCa-2 and Panc-1 are both human ductal pancreatic
carcinoma cell lines and were obtained from the European
Cell Culture Collection. AR42J is a rat pancreatic acinar
tumour cell line and was kindly provided by Dr S. Watson
(Cancer Research Campaign Laboratories, Nottingham Uni-
versity). MiaPaCa-2 and Panc-l were routinely grown in
Dulbecco's Modified Eagle's Medium (DMEM) containing
10% foetal calf serum (ICN Flow, Irvine). AR42J cells were
grown in RPMI 1640 containing 10% FCS (ICN Flow,
Irvine).
The cells were trypsinised and plated out in 96 well plates
at 5 x I04 cells ml-' in serum-free (SF) medium for 24 h.
After this period of serum starvation the medium was supple-
mented with EGF (Sigma, Dorset) or IGF-I (Peninsula, St
Helens) with or without SS-14 (Sigma, Dorset) or RC-160
(Peninsula, St Helens). EGF, IGF-1, SS-14 and RC-160 were
added at concentrations described in the Results section. The
cells were then incubated for 48 h at 37°C. DNA synthesis
was assessed for the final 6 h by adding 0.5 liCi 3H-thymi-
dine/well. The cells were then collected onto filter mats using
a semi-automatic cell harvester (Inotech, Switzerland). Scin-
tillation fluid was added to individual filter discs and the cell
associated radioactivity counted in a beta counter (Packard
1900CA Tricarb).
Binding studies
Binding of ['25I-tyr"]Somatostatin (Amersham International)
was performed on membranes prepared from the three cell
lines. Cells were washed twice with phosphate buffered saline
(pH 7.4), then removed from 150 cm2 flasks using a cell
scraper. After centrifuging at 600 g for 5 min, the super-
natant was discarded and the cells resuspended in 20 mM Tris
buffer (pH 7.4) containing 0.3 M sucrose, 5 mM magnesium
chloride, 0.3 mg ml-' soybean trypsin inhibitor and 0.5 mg
ml-' bacitracin. The cells were lysed with a sonifier (30s)
and centrifuged at 600 g for 5 min. The supernatant was
further centrifuged at 50,000 g for 30 min at 4°C. The result-
ing pellet was resuspended in the Tris buffer without sucrose
and frozen in aliquots at - 70°C. The protein content of the
suspension was determined using a bicinchoninic acid kit
(Pierce, Rockford, USA).
For the displacement binding assays 20pl membrane sus-
pension (2.5-10fig) was incubated with 10ill 1251SS (0.5 nM)
and 10 gAl buffer or unlabelled RC-160 (10-6I- 0-11 M). Incu-
bation buffer consisted of 50 mM Tris, 0.2% BSA, 0.3 mg
ml-' soybean trypsin inhibitor, 0.5 mg ml-' bacitracin and
0.2 mM calcium chloride. The incubation time was 1 h at
30°C. Incubation was terminated by rapid filtration under
reduced pressure through Whatman GF/B filters. The filters
were washed three times with ice-cold buffer containing
50 mM Tris and 0.2% BSA (pH 7.4). To reduce ligand
binding the filter papers were presoaked in 0.5% polyethene-
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imine overnight. After filtration the filters were dried and
counted in a gamma-counter (Packard Cobra).
In saturation binding assays 20 1.l membrane suspension
(2.5tgg) was incubated with 30 l 11251-SS (0.05-1 nM) and
30 gAl buffer or unlabelled RC-160 (1 tM) to define non-
specific binding. The incubation time was 2 h at 30°C. The
binding was terminated with an identical procedure to that
used in displacement assays.
Non-linear regression programmes were used to interpret
binding data (Graph Pad Software Inc., San Diego, CA).
Statistical analysis ofdata
Response of cells to EGF or IGF with or without SS-14 or
RC-160 was analysed for significance by comparing means of
treated cells with the appropriate control by Student's t-test.
increased the proliferation of the two cell lines (P<0.01
compared to untreated cells) (Figure Ib). Addition of neither
SS-14 nor RC-160 had any effect on DNA synthesis in EGF
or IGF-l stimulated MiaPaCa-2 or Panc-1 cells (P>0.05
compared to stimulated cells) (Figures 2 and 3).
Effect ofRC-160 on AR42J cells stimulated with EGF in
serumfree medium
EGF (108 M) caused a significant increase (79 ± 9.9%) in
AR42J proliferation after 48 h of culture (P<0.001 com-
pared to untreated cells). Addition of RC-160 caused a dose-
dependent inhibition of EGF-induced AR42J-growth with a
maximal response between 10-7 M and 10-8 M (P<0.001
compared to stimulated cells) (Figure 4).
Results
Effect ofSS-14 and RC-160 on MiaPaCa-2 and Panc-J grown
with EGF or IGF-I in serumfree medium
Growth experiments were carried out in serum free (SF)
medium because in preliminary experiments serum masked
the stimulatory effects of EGF and IGF-1. Cells were cul-
tured in SF medium for the first 24 h of the experiment in
order to arrest cell growth. The stimulated growth response
to EGF and IGF-1 was then measured by quantifying 3H-
thymidine incorporation into DNA after 48 h. Mean control
values (SF medium) were MiaPaCa-2 677 ± 44 counts per
minute (CPM) and Panc-l 411 + 33 CPM. The optimum
concentration of EGF and IGF-1 was 10'8 M and this con-
centration was added in all subsequent experiments.
EGF stimulated the growth of both cell lines (P<0.01
compared to untreated cells), having a more pronounced
effect on MiaPaCa-2 (Figure Ia). IGF-I also significantly
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Somatostatin binding studies
In competition experiments RC-160 was able to displace 95%
of the radiolabelled somatostatin from AR42J membranes
(Figure 5a). The -logIC50 was calculated to be -9.2, which
was equivalent to a Kd value of 0.26 nM, indicating the
presence of high affinity receptors on AR42J. In contrast no
displaceable binding was detectable on Panc-I or MiaPaCa-2.
When AR42J-membranes were incubated with increasing
concentrations of labelled ligand, specific binding showed a
saturable component (Figure 5b), although we cannot ex-
clude the possibility of a low affinity high capacity binding
site. Non-linear regression analysis of this data resulted in a
Kd of 0.20 ± 0.05 nM and a Bmax of 2126 ± 266 fmoles mg-
protein (data is the mean of three experiments carried out in
triplicate). Over the concentration range studied Scatchard
analysis describes a single population of binding sites (Figure
Sb inset).
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Figure 1 Proliferation of MiaPaCa-2 ( E ) and Panc-I ( _ )
in response to EGF a, and IGF b, as measured by 3H-thymidine
incorporation. Results are expressed as the percentage increase
from control value (SF medium) and are the mean±s.e.m. of
three separate experiments in which five determinations were
made.
Peptide concentration (M)
Figure 2 Proliferation of MiaPaCa-2 ( m ) and Panc-l ( _ )
in response to EGF and RC-160 a, and EGF and SS-14 b, as
measured by 3H-thymidine incorporation. Results are expressed
as the percentage increase from control value (SF medium) and
are the mean±s.e.m. of three separate experiments in which five
determinations were made.
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Figure 3 Proliferation of MiaPaCa-2 ( 1 ) and Panc-1 ( M )
in repsonse to IGF-1 and RC-160 a, and IGF and SS-14 b, as
measured by 3H-thymidine incorporation. Results are expressed
as the percentage increase from control value (SF medium) and
are the mean±s.e.m. of three separate experiments in which five
determinations were made.
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Figure 4 Proliferation of AR42J in response to EGF and RC-
160 as measured by 3H-thymidine incorporation. Results are
expressed as the percentage of the value obtained with EGF
stimulated cells and are the mean ± s.e.m. of three separate
experiments in which five determinations were made.
Discussion
Somatostatin and its analogues have been shown to inhibit
pancreatic cancer growth in vitro and in vivo (Liebow et al.,
1986; 1989; Redding et al., 1984; Upp et al., 1988; Poston et
al., 1990; Szepeshazi et al., 1991). In order for this to be a
direct antiproliferative effect those cells responding to soma-
tostatin should express somatostatin receptors. The present
Free 125I-somatostatin (nM)
Figure 5 Representative displacement plot showing the inhibi-
tion '25l-SS binding to AR42J membranes by unlabelled RC-160
a. Displaceable binding is normalised to 100% and has been
plotted against the log10 of the unlabelled concentration.
Representative saturation plot showing total (- *-) specific
(-*-) and non-specific ( -A--) binding to AR42J b.
Bound '25I-SS is plotted against the free concentration of ligand
added. Scatchard plot of the specific binding is shown (inset).
results demonstrate that, contrary to previous reports, Mia-
PaCa-2 does not express somatostatin receptors and does not
respond in vitro to SS-14 and RC-160. We have also shown
that this is the case for a second human pancreatic cell line
Panc-l.
EGF, TGF-x and IGF-I have been implicated as growth
promoting factors for pancreatic cancer. Korc et al. (1986)
suggested that enhanced expression of the EGF receptor in
human pancreatic cancer may be associated with either struc-
tural or numerical alterations in chromosome 7. The same
group have also shown that various pancreatic cell lines
secrete TGF-a which may therefore act in an autocrine man-
ner as a potent growth promoter (Smith et al., 1987). The
presence of immunoreactive EGF and TGF-c and the over-
expression of EGF receptor has also been shown in an
archival series of human pancreatic cancers (Barton et al.,
1991; Lemoine et al., 1992). Further confirmatory evidence
for this hypothesis was provided by Chen et al. (1990) and
Omhura et al. (1990) who also demonstrated a role for
IGF-1 as an autocrine factor in pancreatic cancer cell pro-
liferation. It was for these reasons that we used EGF and
IGF-I as stimulatory agents for MiaPaCa-2 and Panc-l. A
further reason for selecting EGF was the report that
somatostatin causes the dephosphorylation of the EGF
receptor (Hierowski et al., 1985) thus retarding cell prolifera-
tion (Liebow et al., 1986; 1989). Although this has not been
demonstrated with IGF-I it might be postulated that
somatostatin could effect the IGF-I receptor in a similar
fashion because the IGF-1 receptor also has an internal
tyrosine kinase domain which is important for stimulating
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cell growth. We found that neither SS-14 nor RC-160 was
capable of inhibiting this growth activation. This is in con-
trast to the work of Liebow et al. (1986; 1989) who have
suggested that SS-14 and RC-160 together with another
somatostatin analogue, RC-121, all inhibit the EGF-
stimulated growth of MiaPaCa-2. They did not study these
effects on the Panc-l cell line. By way of a positive control,
we have shown that RC-160 can inhibit the EGF-induced
growth of the AR42J rat acinar cell line. This is consistent
with the report by Viguerie et al. (1989) who have demon-
strated that the somatostatin analogue SMS 201-995 has
direct inhibitory effects on AR42J cell proliferation via a
mechanism independent of a pertussis toxin sensitive GTP-
binding protein.
The present experiments reveal that specific binding sites
for somatostatin are absent from the two human ductal
pancreatic cancer cell lines. Hierowski et al. (1985) demon-
strated somatostatin receptors on MiaPaCa-2 with a very low
Bmax value of 3.6 fmole mg-' protein. However these authors
did not provide data showing total or non-specific binding
curves and no Kd was quoted. Our results are more consis-
tent with the findings of Reubi et al. (1988) who has
examined 12 fresh human pancreatic adenocarcinomas none
of which contained specific somatostatin receptors.
As part of the internal positive control for these experi-
ments we also performed binding experiments on membranes
prepared from the rat acinar tumour cell line AR42J. The
data revealed that AR42J possesses somatostatin receptors
which consist of a single class of high affinity binding sites
with a Kd (0.20 nM) in the range of that observed by other
groups (Viguerie et al., 1989).
Although we chose to study three pancreatic tumour cell
lines it is important to emphasise that the effects and res-
ponse of these cells are not comparable since the AR42J is
rat acinar in origin and the MiaPaCa-2 and Panc-1 are
human ductal in origin. It should be recalled that 80-90% of
cases of pancreatic adenocarcinoma are ductal in origin. Our
purpose in studying the AR42J cell line was to exploit this as
a positive control in an effort to demonstrate that our assay
systems were effective.
It is difficult to explain the inconsistency between previous
findings and our findings with the MiaPaCa-2 cell line. One
possibility is that the receptor status and characteristics of
MiaPaCa-2 cell line have altered with increasing passage
number. One previous study has also suggested that there is
no growth inhibitory effect of somatostatin on these pancrea-
tic cell lines but this study was conducted on unstimulated
cells in serum-free medium at one concentration (Liehr et al.,
1990). However there are no previous reports on the somato-
statin receptor expression by the other pancreatic ductal cell
line Panc-1 which we also conclude to be devoid of func-
tional binding sites. In conclusion we have found no somato-
statin receptors and no growth inhibitory response to
somatostatin in two human pancreatic cancer cell lines. This
supports the evidence from autoradiographic studies which
indicate that very few human pancreatic adenocarcinomas
express somatostatin receptors in vivo (Reubi et al., 1988;
Singh et al., 1991). Furthermore a recent clinical trial of
RC-160 in patients with pancreatic cancer has at best shown
that this agent may cause disease stabilisation of true ductal
adenocarcinoma rather than tumour regression (Poston et al.,
1991). Collectively these finding raise doubts about the role
of somatostatin and its analogues as single agent treatment
options for the majority of human pancreatic cancers.
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